Close the left navigation

Environmental Health Economic Analysis Annotated Bibliography

Go Back

Details

Review
Authors

Sullivan SD and Weiss KB

Journal

Journal of Allergy and Clinical Immunology

Summary
In this review article, the authors described the elements of comparative economic evaluations for asthma and rhinitis in an attempt to critically evaluate studies from the perspective of one who might use data for decision making. The authors suggested that the quality of economic evidence for asthma and rhinitis is limited, and therefore, the allocation of resources for these diseases will continue to primarily rely on expert opinion rather than evidence-based literature.
Population

Not available

Health Outcomes

  • Respiratory outcomes

Health Outcome List:

  • Reviewed publications that examined — respiratory outcomes (asthma, allergic rhinitis)

Environmental Agents

List of Environmental Agents:

  • Not available

Source of Environmental Agents:

  • Not available

Economic Evaluation / Methods and Source

Type:

  • Cost-effectiveness analysis (CEA)

Cost Measures:

  • Reviewed publications that assessed costs associated with asthma and rhinitis, including — Healthcare costs (diagnostic testing)
  • education costs (special education, asthma patient education)
  • productive days lost
  • short-stay observation units

Potential Cost Measures:

  • Not available

Benefits Measures:

  • Not available

Potential Benefits Measures:

  • Not available

Location:

  • Not available

Models Used:

  • Not available

Models References:

  • Not available

Methods Used:

  • The authors performed a concise review of studies of both asthma and allergic rhinitis that highlight the utility of economic evaluations for clinical and resource decision making.

Sources Used:

  • The cost-effectiveness of budesonide in severe asthmatics aged one to three years (Connett et al., 1993); Efficacy and cost benefit of inhaled corticosteroids in patients considered to have mild asthma in primary care (O'Byrne et al., 1996); Cost-effectiveness of salmeterol/fluticasone propionate combination product 50/250 micrograms twice daily in the treatment of adults and adolescents with asthma (Lundback et al., 2000); additional sources cited in publication

Economic Citation / Fundings

Citation:

  • Sullivan SD and Weiss KB. Health economics of asthma and rhinitis. II. Assessing the value of interventions. Journal of Allergy and Clinical Immunology. 2001. 107; 2.
  • Pubmed
  • DOI

NIEHS Funding:

  • Not available

Other Funding: Not available